4 results
We aim to assess differences in the in vivo distribution of CD8+ T-cells in patients with proven SARS-CoV-2 presenting with lymphopenia or with normal lymphocyte counts, using [89Zr]Zr-Df-IAB22M2C PET/CT imaging. Elucidating the pathophysiology…
Primary Objective:To evaluate the efficacy potential, safety and tolerability of intravenously administered ANXV, in ascending doses, and two different dosing regimens, in patients with confirmed moderate to severe COVID-19.Secondary Objectives:To…
The primary objectives1. To assess the safety and tolerability of intravenous tracer administration of ANXV-800CW in up to three doses (0.5 mg, 1.0 mg, 2.0 mg flat dose) in patients with RVO and/or DR2. To determine the feasibility of molecular…
The primary objective of the trial is to assess a non-flat dose-response curve and to evaluate the dose-response relationship for 3 oral dose regimens of BI 1291583 versus placebo, on the primary endpoint, time to first pulmonary exacerbation up to…